Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CALGB 80802 trial: what clinicians have said so far
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- NCT01015833 ↗
- Completed
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on CALGB 80802 (sorafenib plus doxorubicin in advanced hepatocellular carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CALGB 80802 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Advanced Adult Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Unresectable Hepatocellular Carcinoma
- Interventions
- Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Pharmacogenomic Study; Sorafenib Tosylate
- Arms
- Arm I (doxorubicin hydrochloride, sorafenib tosylate) · Experimental
- Arm II (sorafenib tosylate) · Experimental
- Enrollment
- 356
- Primary outcomes
- Overall Survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 15, 2010
- Primary completion
- May 21, 2015
- Results posted
- Yes
- Registry record
- NCT01015833 · updated Jun 24, 2026
Publications
linked from the registry- Quintanilha JCF, Geyer S, Etheridge AS, Racioppi A, Hammond K, Crona DJ, Pena CE, Jacobson SB, Marmorino F, Rossini D, Cremolini C, Sanoff HK, Abou-Alfa GK, Innocenti F. KDR genetic predictor of toxicities induced by sorafenib and regorafenib. Pharmacogenomics J. 2022 Dec;22(5-6):251-257. doi: 10.1038/s41397-022-00279-3. Epub 2022 Apr 28. PubMed 35484400
- Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792. PubMed 31486832